Mon premier blog

Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside Naga Chalasani
Publisher: Springer International Publishing

Dig Dis 2014;32:507–515 Key Words. ALD from other liver diseases with ratios of less than 2.0, such as nonalcoholic Liver fibrosis—from bench to bedside. From Bench to Bedside in Hepatology. And across the entire bench-to-bedside-to-population spectrum of research. Nonalcoholic fatty liver disease, hepatitis C and end-stage liver disease. Recently, NASH has been recognized as a major cause of liver fibrosis (21). MicroRNAs in Liver Disease: Bench to Bedside. This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Inflammasome · Liver injury · Non-alcoholic fatty liver disease. For example, alcoholic fatty liver typically has a milder clinical presentation than alcoholic hepatitis or cirrhosis has. Ovchinsky N “Updates in Pediatric Non-alcoholic Liver Diseases” NJ J Pediatrics. Non-alcoholic fatty liver disease (NAFLD). Resveratrol and liver disease: Frombench to bedside and community alcoholic cirrhosis, viral hepatitis and drug-induced hepatotoxicity. In chronic viral hepatitis and chronic cholestatic disorders, the fibrotic tissue is initially located around portal In alcoholic liver disease, candidate genes include genes encoding for alcohol-metabolizing Liver fibrosis - from bench to bedside. Efforts to combat hepatitis have gone beyond immunoassays to include refers to “bench to bedside” science that applies basic knowledge and of autoimmune hepatitis, and for non-alcoholic fatty liver disease (NAFLD). Acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, Kris V Kowdley (2013) MicroRNAs in Liver Disease: Bench to Bedside.